Idioma:

Targeting embryonic signaling pathways in cancer therapy

Harris, Pamela Jo ; Speranza, Giovanna ; Dansky Ullmann, Claudio

Expert opinion on therapeutic targets, 2012-01, Vol.16 (1), p.131-145 [Periódico revisado por pares]

England: Informa UK, Ltd

Sem texto completo

Citações Citado por

Enviar para

Título:
Targeting embryonic signaling pathways in cancer therapy
Autor: Harris, Pamela Jo ; Speranza, Giovanna ; Dansky Ullmann, Claudio
Assuntos: Animals ; Antineoplastic Agents - therapeutic use ; cancer ; cancer stem cells ; developmental pathways ; embryonic signaling pathways ; Hedgehog ; Hedgehog Proteins - metabolism ; Humans ; Neoplasms - drug therapy ; Neoplasms - metabolism ; Neoplastic Stem Cells - drug effects ; Neoplastic Stem Cells - metabolism ; Notch ; Receptors, Notch - metabolism ; Signal Transduction - drug effects ; Wnt ; Wnt Proteins - metabolism
É parte de: Expert opinion on therapeutic targets, 2012-01, Vol.16 (1), p.131-145
Notas: ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
Descrição: Introduction: The embryonic signaling pathways (ESP), Hedgehog, Notch and Wnt, are critical for the regulation of normal stem cells and cellular development processes. They are also activated in the majority of cancers. ESP are operational in putative cancer stem cells (CSC), which drive initial tumorigenesis and sustain cancer progression and recurrence in non-CSC bulk subpopulations. ESP represent novel therapeutic targets. A variety of inhibitors and targeting strategies are being developed. Areas covered: This review discusses the rationale for targeting ESP for cancer treatment, as well as specific inhibitors under development; mainly focusing on those approaching clinical use and the challenges that lie ahead. The data sources utilized are several database search engines (PubMed, Google, Clinicaltrials.gov), and the authors' involvement in the field. Expert opinion: CSC research is rapidly evolving. Expectations regarding their therapeutic targeting are rising quickly. Further definition of what constitutes a true CSC, proper validation of CSC markers, a better understanding of cross-talk among ESP and other pathways, and interactions with tumor non-CSC and the tumor microenvironment are needed. The appropriate patient population, the right clinical setting and combination strategies to test these therapies, as well as the proper pharmacodynamic markers to measure, need to be further established.
Editor: England: Informa UK, Ltd
Idioma: Inglês

Links

View this record in MEDLINE/PubMed

Voltar para lista de resultados

Realização: Logos de Redes Sociais:

Targeting embryonic signaling pathways in cancer therapy

Harris, Pamela Jo ; Speranza, Giovanna ; Dansky Ullmann, Claudio

England: Informa UK, Ltd

Buscando em bases de dados remotas. Favor aguardar.